{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Australia/Sydney", "exchangeTimezoneShortName": "AEST", "currency": "AUD", "market": "au_market", "esgPopulated": false, "gmtOffSetMilliseconds": 36000000, "exchange": "ASX", "longName": "Pharmaxis Ltd", "shortName": "PHARMAXIS FPO", "regularMarketPrice": 0.052, "regularMarketChangePercent": 1.9607882, "messageBoardId": "finmb_3110465", "marketState": "PRE", "fiftyTwoWeekHighChangePercent": -0.41573033, "fiftyTwoWeekLow": 0.042, "fiftyTwoWeekHigh": 0.089, "earningsTimestamp": 1682634379, "earningsTimestampStart": 1682634379, "earningsTimestampEnd": 1682634379, "trailingAnnualDividendRate": 0.0, "trailingPE": 5.2000003, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 0.010000002, "fiftyTwoWeekLowChangePercent": 0.23809528, "fiftyTwoWeekRange": "0.042 - 0.089", "fiftyTwoWeekHighChange": -0.037, "epsTrailingTwelveMonths": 0.01, "epsForward": -0.01, "epsCurrentYear": -0.02, "priceEpsCurrentYear": -2.6000001, "sharesOutstanding": 719518016, "bookValue": 0.022, "fiftyDayAverage": 0.05104, "fiftyDayAverageChange": 0.00095999986, "fiftyDayAverageChangePercent": 0.018808775, "twoHundredDayAverage": 0.063695, "twoHundredDayAverageChange": -0.011694998, "twoHundredDayAverageChangePercent": -0.18360935, "marketCap": 38885756, "forwardPE": -5.2000003, "priceToBook": 2.3636365, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1068418800000, "priceHint": 4, "regularMarketChange": 0.001000002, "regularMarketTime": 1683784662, "regularMarketDayHigh": 0.052, "regularMarketDayRange": "0.051 - 0.052", "regularMarketDayLow": 0.051, "regularMarketVolume": 27937, "regularMarketPreviousClose": 0.051, "bid": 0.05, "ask": 0.052, "fullExchangeName": "ASX", "financialCurrency": "AUD", "regularMarketOpen": 0.051, "averageDailyVolume3Month": 407066, "averageDailyVolume10Day": 365636, "symbol": "PXS.AX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "20 Rodborough Road", "city": "Frenchs Forest", "state": "NSW", "zip": "2086", "country": "Australia", "phone": "61 2 9454 7200", "fax": "61 2 9451 3622", "website": "https://www.pharmaxis.com.au", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gary Jonathan Phillips BPharm, MBA", "age": 61, "title": "CEO, MD & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 613726, "fmt": "613.73k", "longFmt": "613,726"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David Morris McGarvey BA, CA, CPA", "age": 66, "title": "CFO & Company Sec.", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 514903, "fmt": "514.9k", "longFmt": "514,903"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D.", "age": 58, "title": "Head of Drug Discovery", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 464682, "fmt": "464.68k", "longFmt": "464,682"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kristen  Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin", "age": 50, "title": "Head of Medical & Regulatory Affairs - Alliance Management", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 285088, "fmt": "285.09k", "longFmt": "285,088"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jana  Baskar", "title": "Chief Medical Officer", "fiscalYear": 2022, "totalPay": {"raw": 554262, "fmt": "554.26k", "longFmt": "554,262"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Cameron David Billingsley", "age": 45, "title": "Gen. Counsel", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}